164 related articles for article (PubMed ID: 2550692)
1. Abnormal plasma prothrombin (PIVKA-II) levels in hepatocellular carcinoma.
Kawaguchi Y
Jpn J Surg; 1989 May; 19(3):296-300. PubMed ID: 2550692
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma.
Deyashiki Y; Nishioka Y; Takahashi K; Kosaka Y; Suzuki K
Cancer; 1989 Dec; 64(12):2546-51. PubMed ID: 2555040
[TBL] [Abstract][Full Text] [Related]
3. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.
Nakao A; Virji A; Iwaki Y; Carr B; Iwatsuki S; Starzl E
Hepatogastroenterology; 1991 Oct; 38(5):450-3. PubMed ID: 1722483
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
[TBL] [Abstract][Full Text] [Related]
5. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
[TBL] [Abstract][Full Text] [Related]
6. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
[TBL] [Abstract][Full Text] [Related]
7. Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases.
Mohamedein A; Yousif-Kadaru AG; Ahmed SA; Saida H; Zaki ZA; Eldin ; Fedail SS
East Afr Med J; 1995 Sep; 72(9):584-7. PubMed ID: 7498046
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
[TBL] [Abstract][Full Text] [Related]
9. [The clinical significance of PIVKA-II determination in patients with hepatocellular carcinoma: a comparative study with alpha-fetoprotein].
Sakon M; Monden M; Goto M; Kanai T; Umeshita K; Endo W; Mori T
Nihon Geka Gakkai Zasshi; 1990 May; 91(5):588-93. PubMed ID: 1696680
[TBL] [Abstract][Full Text] [Related]
10. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma.
Nakagawa T; Seki T; Shiro T; Wakabayashi M; Imamura M; Itoh T; Tamai T; Nishimura A; Yamashiki N; Matsuzaki K; Sakaida N; Inoue K; Okamura A
Int J Oncol; 1999 Feb; 14(2):281-6. PubMed ID: 9917503
[TBL] [Abstract][Full Text] [Related]
12. Acarboxy prothrombin (PIVKA-II) as a marker of hepatoblastoma in infants.
Motohara K; Endo F; Matsuda I; Iwamasa T
J Pediatr Gastroenterol Nutr; 1987; 6(1):42-5. PubMed ID: 2432210
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
[TBL] [Abstract][Full Text] [Related]
14. Abnormal prothrombin: evaluation as a tumour marker and localization in tissues of patients with hepatocellular carcinoma.
Koda T; Yamazaki S; Tamura I; Nakaba H; Takao T; Katayama S; Kurimura O
J Gastroenterol Hepatol; 1993; 8(3):212-6. PubMed ID: 7686054
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of PIVKA-II After Living-donor Liver Transplantation for Hepatocellular Carcinoma.
Park MS; Lee KW; Kim H; Choi YR; Hong G; Yi NJ; Suh KS
Transplant Proc; 2017 Jun; 49(5):1109-1113. PubMed ID: 28583537
[TBL] [Abstract][Full Text] [Related]
16. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
Fujiyama S; Morishita T; Shibata J; Sato T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic value of serum alpha-fetoprotein, alpha-fetoprotein variant and abnormal prothrombin in primary hepatocellular carcinoma].
Hu RZ; Zhao SQ; Shen B; Guo GB
Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):634-637. PubMed ID: 31594082
[No Abstract] [Full Text] [Related]
18. Epitope characterization of an anti-PIVKA-II antibody and evaluation of a fully automated chemiluminescent immunoassay for PIVKA-II.
Kinukawa H; Shirakawa T; Yoshimura T
Clin Biochem; 2015 Nov; 48(16-17):1120-5. PubMed ID: 26297114
[TBL] [Abstract][Full Text] [Related]
19. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yoon YJ; Han KH; Kim DY
Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
[TBL] [Abstract][Full Text] [Related]
20. A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma.
Sohn A; Kim H; Yu SJ; Yoon JH; Kim Y
Anal Bioanal Chem; 2017 Apr; 409(11):2829-2838. PubMed ID: 28168546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
